“An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program With More Than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S116. Accessed April 14, 2025. https://skin.dermsquared.com/skin/article/view/498.